Analyst firms · Wedbush · ZNTL
Wedbush ZNTL price target and rating history
Zentalis Pharmaceuticals Inc. (ZNTL) · Health Care
Wedbush rates Zentalis Pharmaceuticals Inc. (ZNTL) Outperform with a $6 price target, as of its latest action on Nov 10, 2026. It has published 4 rating actions on ZNTL since November 2023, including 2 upgrades and 2 downgrades. Across 5 firms with a ZNTL price target in the last 12 months, the median target is $8. Wedbush's $6 is 25% below that.
- Current rating
- Outperform
- Price target
- $6
- Median target, all firms
- $8
- Actions on ZNTL
- 4
Wedbush price target on ZNTL
Every Wedbush rating on ZNTL
- Nov 10, 2026
- Aug 12, 2024
- Jun 18, 2024
- Nov 8, 2023
How other firms rate ZNTL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wedbush | Outperform | $6 | Nov 10, 2026 |
| Leerink Partners | Outperform | $8 | Oct 5, 2026 |
| Wells Fargo | Equal Weight | $5 | Sep 30, 2026 |
| William Blair | Outperform | Sep 16, 2026 | |
| Rodman & Renshaw | Buy | $11 | Jul 23, 2026 |
| Mizuho | Outperform | $8 | Jul 17, 2026 |
Questions about Wedbush and ZNTL
- What is Wedbush's price target for ZNTL?
- Wedbush's latest stated price target for Zentalis Pharmaceuticals Inc. (ZNTL) is $6, from its action on Nov 10, 2026.
- What is Wedbush's rating on ZNTL?
- Wedbush rates ZNTL Outperform, a bullish rating, as of Nov 10, 2026.
- When did Wedbush last change its view on ZNTL?
- On Nov 10, 2026, Wedbush upgrades to Outperform from Neutral, price target $6.
- How does Wedbush's ZNTL target compare with other analysts?
- Across 5 firms with a ZNTL price target in the last 12 months, the median target is $8. Wedbush's $6 is 25% below that.
More ZNTL rating histories
All Wedbush ratingsZNTL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.